Extent-based tailored strategy for rectal cancer with resectable synchronous liver metastases: Long-term oncologic results of a multicentric cohort study.

Abstract

There is no standard surgical management for rectal cancer with synchronous resectable liver metastases. The aim of this study was to assess the oncologic outcomes of an adaptative and individualized strategy considering the extension of both tumoral sites in the management of rectal cancer with synchronous resectable liver metastases. From 2011 to 2020, all consecutive patients treated for low/midrectal cancer with resectable synchronous resectable liver metastases in 4 French centers were included. The choice of strategy was not systematic but tailored on a case-by-case basis to the extension of rectal cancer and liver metastases, prioritizing the most advanced site. The success of the strategy was defined as complete resection of both tumor sites. Among 83 included patients, most had locally advanced rectal cancer (cT3T4 = 96%) and a median of 3 liver metastases. Forty patients underwent a rectum-first strategy, 31 a liver-first strategy, and 12 a simultaneous resection strategy. Complete resection rate of both sites was 82%. After a 43-month follow-up, median overall survival was 58 months. One- and 3-year survival rates were 94% and 73%, with no difference between strategies (P = .650). In multivariate analysis, the only prognostic factor for overall survival was complete resection of both sites (P = .011, hazard ratio, 0.321; 95% confidence interval, 0.135-0.768), with a median overall survival of 72 months in these patients. Extent-based tailored strategy for rectal cancer with synchronous resectable liver metastases, on the basis of disease extension, allows high rates of complete resection and favorable long-term survival outcomes. This individualized approach maximizes potential for curative outcomes in patients with metastatic rectal cancer.